Page 15 - Robert Jaffe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lannett Development Of Biosimilar Insulin Glargine Product Continues To Advance --FDA Provides Feedback on Pivotal Trial Protocol and Statistical Analysis Plan-- News provided by Share this article Share this article PHILADELPHIA, March 10, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it recently received feedback from the U.S. Food and Drug Administration (FDA) regarding biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC). Lannett sought and received comments from the ...

Operator Welcome to the Lannett Company's Fiscal 2021 Second Quarter Financial Results Conference Call. My name is Adrian. I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded. I will now turn the call over to Robert Jaffe. Robert Jaffe, you may begin. Robert Jaffe Good afternoon, everyone. And thank you for joining us today to discuss Lannett Company's fiscal 2021 second quarter financial results. On the call today are Tim Crew, Chief Executive Officer; and John Kozlowski, the company's Chief Financial Officer; and Maureen Cavan...

Share this article Share this article PHILADELPHIA, Jan. 27, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 second quarter on Wednesday, February 3, 2021, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions. The conference call will be available to interested parties by dialing 800-447-0521 from the U.S. or Canada, or 847-413-3238 from international locations, passcode 50088413. The call wi...